Christopher Richard Anzalone Sells 51,425 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Christopher Richard Anzalone sold 51,425 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $15.07, for a total transaction of $774,974.75. Following the transaction, the chief executive officer now owns 4,062,377 shares of the company’s stock, valued at approximately $61,220,021.39. This represents a 1.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Christopher Richard Anzalone also recently made the following trade(s):

• On Tuesday, March 4th, Christopher Richard Anzalone sold 133,333 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $17.02, for a total transaction of $2,269,327.66.
• On Thursday, January 2nd, Christopher Richard Anzalone sold 11,520 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $19.05, for a total transaction of $219,456.00.
• On Monday, December 23rd, Christopher Richard Anzalone sold 12,563 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $19.59, for a total transaction of $246,109.17.
• On Wednesday, December 18th, Christopher Richard Anzalone sold 26,712 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $21.24, for a total transaction of $567,362.88.

Arrowhead Pharmaceuticals Stock Performance

Shares of Arrowhead Pharmaceuticals stock opened at $15.10 on Wednesday. The stock has a market cap of $2.07 billion, a price-to-earnings ratio of -2.92 and a beta of 0.92. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $14.23 and a twelve month high of $30.41. The company’s fifty day moving average is $18.83 and its 200 day moving average is $20.05.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.97). Sell-side analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. R Squared Ltd acquired a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at about $38,000. GF Fund Management CO. LTD. acquired a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at about $49,000. Van ECK Associates Corp raised its holdings in shares of Arrowhead Pharmaceuticals by 72.3% during the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 1,250 shares during the period. KBC Group NV raised its holdings in shares of Arrowhead Pharmaceuticals by 45.9% during the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 1,644 shares during the period. Finally, Mackenzie Financial Corp acquired a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at about $137,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

Analysts Set New Price Targets

ARWR has been the topic of a number of research reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. Piper Sandler decreased their target price on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 27th. Sanford C. Bernstein decreased their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating on the stock in a research note on Friday, November 29th. Citigroup decreased their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 27th. Finally, StockNews.com raised shares of Arrowhead Pharmaceuticals to a “sell” rating in a research note on Friday, December 20th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $41.44.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.